ReviewCureus2026
Circulating Orexin-A Levels in Patients With Schizophrenia, Bipolar Disorder, and Major Depressive Disorder: A Systematic Review and Meta-Analysis.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Orexin-A, a neuropeptide involved in regulating physiological processes, has potential implications in psychiatric disorders. Studies examining orexin-A levels in schizophrenia, bipolar disorder, and major depressive disorder have produced conflicting results, highlighting the need for further research. To address these inconsistencies, this meta-analysis aims to synthesize existing data on orexin-A levels across these disorders, clarifying its role and potential as a diagnostic or prognostic biomarker. This systematic review, registered with PROSPERO, investigated plasma orexin-A levels in schizophrenia, bipolar disorder, and major depressive disorder. Relevant studies were identified through PubMed and PsycINFO using specific keywords. Inclusion criteria targeted adult patients with these disorders and healthy controls, assessing quality and bias using the MINORS tool for non-randomized studies and the AXIS tool for cross-sectional studies. A meta-analysis compared orexin-A levels between groups, using random-effects models and evaluating statistical heterogeneity and publication bias. Of the 64 reviewed articles in full-text screening, 11 met the criteria for analysis, involving 1,778 participants (514 with schizophrenia, 149 with bipolar disorder, and 461 with major depressive disorder). The meta-analysis revealed significantly decreased plasma orexin-A levels in schizophrenia (SMD = -0.38; 95% CI: -0.72 to -0.05; p = 0.03) and increased levels in major depressive disorder (SMD = 0.38; 95% CI: 0.15 to 0.60; p = 0.001) compared to healthy controls. Moderate statistical heterogeneity was noted in the schizophrenia analysis (I^2 = 54%). Methodological quality was generally high; MINORS scores ranged from 12 to 20 (out of 24), and AXIS scores ranged from 17 to 19 (out of 20), indicating a moderate-to-low risk of bias. These findings suggest distinct orexin-A dysregulation in schizophrenia and major depressive disorder. However, findings in bipolar disorder were inconclusive due to high heterogeneity, indicating orexin-A's complex involvement in mood and energy regulation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.